Download Files:
DCZ0415
$145 – $1,575
Products Details
Product Description
– DCZ0415, a potent TRIP13 inhibitor, impairs nonhomologous end joining repair and inhibits NF-κB activity. DCZ0415 induces anti-myeloma activity in vitro, in vivo, and in primary cells derived from drug-resistant myeloma patients[1].
Web ID
– HY-130603
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Cancer-programmed cell death
Molecular Formula
– C23H20N2O2
References
– [1]Wang Y, et al. A Small Molecule Inhibitor Targeting TRIP13 suppresses multiple myeloma progression. Cancer Res. 2019 Nov 15. pii: canres.3987.2018.
CAS Number
– 2242470-43-3
Molecular Weight
– 356.42
Compound Purity
– 99.77
SMILES
– O=C1N(C2=CC=C(CC3=CC=NC=C3)C=C2)C(C4C5C(C6)C6C(C=C5)C14)=O
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– DMSO : 62.5 mg/mL (ultrasonic)
Target
– Apoptosis;NF-κB
Isoform
– NF-κB
Pathway
– Apoptosis;NF-κB
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
